Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Wednesday. The brokerage issued a hold rating on the stock.

Trinity Biotech Price Performance

NASDAQ:TRIB opened at $0.82 on Wednesday. The company has a 50 day moving average price of $0.85 and a 200-day moving average price of $1.32. Trinity Biotech has a 1-year low of $0.73 and a 1-year high of $3.55. The firm has a market cap of $14.76 million, a price-to-earnings ratio of -0.36 and a beta of 1.03.

Institutional Investors Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 7.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the quarter. Hunter Associates Investment Management LLC owned 4.72% of Trinity Biotech worth $390,000 at the end of the most recent reporting period. Institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.